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Summary
Background: Supervised injecting facilities (SIF) are intended to reduce the harm related to illicit intravenous drug use. 
Aim: The aim of the study was to map the location of current injecting practices of people who inject drugs (PWID) 
in Cork, Ireland, and to document the related high risk behaviours, ahead of a planned supervised injecting facility. 
Methods: A cross sectional survey, utilizing geo -mapping software (GMS) mapping, was offered to PWID, at sites with-
in the homeless services, needle exchange, and addiction services. Data was analysed using GPS mapping, and descriptive 
and inferential statistics. Results: 51 PWID completed the survey (98% response), 66.67% were male. The age range was 
20-55 years (mean age 30.78 years). 56.9% were in stable accommodation, with 43.1% currently homeless. 92.16% had 
been tested for HIV/Hepatitis C. 31.5% reported injecting into “high risk” areas (groin and neck), 72.55% injected alone. 
58.82% reported injecting at least three times/day, 35.29% reported injecting at least four times/day. 54.9% reported shar-
ing equipment/needles. 58.82% had previously overdosed. 89.3% of recalled overdoses involved an emergency services 
response. Correlation between history of accidental overdose, and injecting alone was statistically significant (p = 0.039), 
as was previous history of overdose and injecting at least three times per day (p = 0.012). 86.27% indicated they would 
use a SIF. A mapping exercise presented visual information around injecting sites, locations of overdoses, fatal overdoses, 
and preferred location of the SIF. Conclusions: The study provides an understanding of PWID profile and risk behav-
iours, alongside a geospatial analysis of injecting, overdose and potential location of a SIF in Cork, Ireland. The findings 
are intended to inform SIF location, and would allow dynamic comparison of both geographic and behavioural changes 
injecting drug use over time, post SIF provision. 
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1. Introduction
Supervised Injecting Facilities (SIF) form a 
controversial part of harm reduction programming 
for drug users [5, 7, 12, 13, 18, 30, 35, 40, 51]. They 
aim to reach and engage with high-risk drug users, 
who are not ready or willing to quit drug use. The 
recent 2016 European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) analysis of SIF de-
scribes three models of delivery; integrated, special-
ized and mobile [9]. Integrated facilities are incor-
porated into low-threshold facilities and attempt to 
address social care including showers, clothing, food, 
as well as care of the injecting health issues. Special-
ized facilities confine themselves only to the inject-
ing health problems including hygienic injecting, 
medical observation and intervention when needed. 
Mobile facilities may be geographically more flex-
ible, but this limits their effectiveness [41]. Over time 
there is evidence of improved public acceptance of 
SIF and no increase in drug-related crime [49]. The 
2006 report commissioned by the Joseph Rowntree 
Foundation in the United Kingdom could not find any 
associated increase in drug use, or that the SIF attract-
ed drug users from other geographical areas, both of 
which had been raised as community concerns in ad-
vance of SIF in an area [19].
As a public health intervention, SIF generally 
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aim to address the issues of dangerous injecting prac-
tices, including groin and neck injecting; unhygienic 
and dangerous environments, where persons may in-
ject alone, and are open to the elements; reduce inci-
dence of overdose, and help prevent spread of blood 
borne viruses (BBV) such as HIV and Hepatitis C 
(HCV) [37, 50]. A cost-benefit analysis conducted by 
Irwin et al in 2017 found that for every dollar spent 
on a SIF, $2.33 would be saved [17]. This saving was 
from five public health outcomes: reducing incidence 
of HIV/HCV, reduced skin and soft tissue infection 
(SSTI), averted overdose deaths, and increased med-
ication-assisted treatment uptake. SIF also attempt to 
address broader community public health issues such 
as reducing the dangers associated with discarded 
drug paraphernalia, and reduce the associated stig-
ma attached to drug use, as “dirty” stigmatised habit 
[48]. An extension of SIF includes increased access 
to education and treatment entry, and reduced callout 
by the emergency medical services to both overdoses 
and poorly responsive drug induced intoxication [40]. 
Outcomes include improved interaction with chronic 
drug users and in doing so increasing uptake into ad-
diction treatment [1, 8, 39, 43]. 
Currently, eight European countries, including 
Switzerland provide SIF [9]. The EMCDDA reports 
that within the seven European Member States (Den-
mark, France, Germany, the Netherlands, Luxem-
bourg, Spain and Norway), there are 78 SIF in opera-
tion [9, 42]. As of 2017, the EMCDDA reported that 
there are; 31 in the Netherlands, 24 in Germany, 13 
in Spain, 12 in Switzerland, five in Denmark, two in 
Norway, two in France and one in Luxemburg [9]. 
Many studies identify that people who inject drugs 
(PWID) would be happy to attend such facilities, [21, 
46] but do not mention where they would prefer it to 
be located, nor objectively analyze where the issues 
it hoped to address were in fact centred. Few stud-
ies have mapped where PWID actually inject, inject 
alone, overdose, or would suggest to have a SIF [10, 
24, 33, 35, 50]. There is a lack of evidence prior to 
opening such facilities, as to how decisions were in-
formed in maximizing the advantage of its location 
[6]. 
Hence, we present findings which underpin de-
cisions around SIF location in the southern city of 
Cork, Ireland, where services had noted increases in 
dangerous injecting practices among PWID includ-
ing a rise in groin injecting, and unsafe environments 
in which PWID prepare their hit [3]. The study was 
undertaken against a backdrop of concern around the 
growing issue of visible drug littering, incidences of 
needle stick injury among the non-drug using pub-
lic, and Dublin HIV outbreak among PWID [11]. In 
2017, the Misuse of Drugs (Supervised Injecting Fa-
cilities) Act was enacted in order to licence SIF in 
Ireland [16].
Aim: The aim of the study was to map the loca-
tion of current injecting practices of PWID in Cork, 
Ireland, and to document the related high risk behav-
iours, ahead of a planned SIF.
2. Methods 
2.1. Design of the study
A cross-sectional descriptive study was con-
ducted which aimed to profile and map service user 
needs in the PWID population in Cork, Ireland, and 
utilize geo -mapping software (GMS) to inform the 
location need of a SIF. 
A survey, utilizing GMS, was offered to PWID, 
at sites within the homeless services, needle ex-
change, and addiction services. The survey was 
administered as a one to one interview by a single 
clinician. Questions included information about in-
jecting practices, experiences of personal and peer 
overdose, risk behaviours, and preferred location for 
a SIF. Participants were asked to map injecting habits 
and needs, to try to capture the geographic spread of 
injecting locations, of associated overdose locations, 
and drug deaths. A series of questions were asked, 
including utilizing Google-maps to pinpoint locations 
within the city on a map, to help identify where risky 
behaviour in relation to injecting drugs was occur-
ring. With the use of Geographic Information Sys-
tem (GIS) Software, this could be cross-referenced to 
known services, including emergency departments, 
needle exchange sites, addiction services, and emer-
gency homeless accommodation and ultimately to the 
service user’s preferred location for a SIF. Core ques-
tions included; geographically, where were the issues 
occurring that a SIF would seek to address in terms of 
injecting, overdoses & related deaths; to what extent 
can the results be stratified according to the level of 
risky behaviour in terms of more frequent injecting, 
injecting in public/alone, frequency of previous over-
dose, associated deaths; and to what extent are these 
issues/risks currently geographically cross-referenced 
to known services, such as emergency departments, 
needle exchange sites, addiction services, emergency 
homeless accommodation, and by the service user’s 
preferred location for a SIF.
Ethical approval for the study was granted by 
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the Social Research Ethics Committee (S.R.E.C.), 
University College Cork, Ireland. A participant infor-
mation sheet, consent and a copy of the topics to be 
covered at the researcher administered survey were 
discussed with each potential participant by the clini-
cian (author one). Potential participants were asked to 
confirm their willingness to participate by indicating 
their consent and to answer the short questionnaire, 
and were given the option of withdrawal at any time 
during the course of the questionnaire. 
2.2. Sample
The study was confined to adult participants 18 
years and older, and those who reported current in-
jecting use of drugs within the past six months. Par-
ticipants were recruited based on convenience, from 
those attending medical clinics in the addiction ser-
vices, homeless services, and needle exchange ser-
vices in the city. Persons would be excluded if they 
were not felt capable of understanding, or consenting 
to the questions being asked. This was facilitated over 
three months from June 1st 2017.
2.3. Data analysis
Data management was carried out in accord-
ance with current General Data Protection Regula-
tion (GDPR) and in accordance with ethical approval 
guidelines. Analysis of data was conducted using GPS 
mapping, and descriptive and inferential statistics. 
Descriptive statistics were used to summarize and 
analyse the data using the statistical software Stata 
version 13.1 (StataCorp, Texas, USA). Analyzed data 
are presented as either percentages or as numbers in 
frequency distribution tables. Age group, accommo-
dation status [homeless/not], history of overdose or 
history of skin infection in the previous 3 months was 
tested for an association against the high risk inject-
ing (groin/neck), injecting alone, or injecting at least 
three times daily, using the chi-square test. Associa-
tions between the venue type for injecting [private ac-
commodation, public building or open/street space] 
was tested against age group, accommodation status, 
history of overdose, sharing of injecting parapherna-
Table 1. How often do you inject?
Answer choices Responses
N %
Weekly 3 5.8
Every couple of days 2 3.9
Daily 7 13.7
Twice daily 9 17.6
Three times daily 12 25.5
Four times daily 9 17.6
Five times daily 9 17.6
Total 51 100.0
Graph 1. How do you usually inject? [Multiple choices allowed] 
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lia, or skin infection using the chi-square test also. 
Finally the history of sharing injecting paraphernalia 
was tested for an association with history of HCV/
HIV testing. A p-value of <0.05 was considered sta-
tistically significant. GMS provided a useful tool to 
help visualize the data provided by PWID, and helps 
describe where in the city a SIF would be placed, 
while comparing this to the service user’s preferred 
location for a SIF. GMS software, ArcGIS was used 
to try to capture the current geographic spread of in-
jecting locations, previous overdose locations, and 
known deaths from overdose. This is cross-referenced 
to known services, including emergency departments, 
needle exchange facilities, addiction services, and ex-
isting needle bins. 
3. Results
3.1. Participant Profile
51 PWID completed the survey (98% response), 
of which 66.67% were male. The age range was 20-
55 years (mean age 30.78 years). 56.9% were in sta-
ble accommodation, with 43.1% currently homeless. 
3.2. Injecting Practices
92.16% had been tested for HIV/Hepatitis C, 
with only 50.98% tested in the past six months. This is 
concerning given that 54.9% reported sharing equip-
ment/needles. No association was found between 
sharing equipment/needles and being tested for HCV/
HIV. 31.5% reported injecting into “high risk” areas 
(groin and neck), and 72.55% injected alone, which 
places them at higher risk should they overdose, with 
no one available to call for help. These sites are close 
to significant arteries and nerves, and so leave the 
user at risk of catastrophic arterial sequelae, or neural 
damage, if the injection is misplaced. PWID usually 
resort to these sites when they no longer can find pe-
ripheral venous access. See Chart 1.
Table 1 gives an indication of how often PWID 
would need to access a SIF. 58.82% reported inject-
ing at least three times/day, while 35.29% reported 
injecting at least four times/day. 54.9% reported shar-
ing equipment/needles. 21.57% reported a SSTI, and 
13.7% had attended the emergency services in the 
previous three months.
Although no association was recorded in be-
tween the older age group and injecting alone (72.7% 
Table 2. Association between Age & High Risk Injecting
High Risk Injecting
Aged 35 years or 
older
No Yes Total
No
 Count 26 9 35
% within Aged 35 years or older 65.0% 81.8% 68.6%
Yes, into groin/neck
Count 14 2 16
% within Aged 35 years or older 35.0% 18.2% 31.4%
Total
Count 40 11 51
% within Aged 35 years or older 100.0% 100.0% 100.0%
The ² statistic is 1.133. The Fisher’s exact is 0.466. The result is not significant at p 0.287
Table 3.  Association between Overdose History and Injecting Alone
Injects Alone
Accidentally overdosed?
Yes No Total
0
Count 5 9 14
% within Have you ever accidentally 
gone over/overdosed? 16.7% 42.9% 27.5%
Alone
Count 25 12 37
% within Have you ever accidentally 
gone over/overdosed? 83.3% 57.1% 72.5%
Total
Count 30 21 51
% within Have you ever accidentally 
gone over/overdosed? 100.0% 100.0% 100.0%
The χ² statistic is 4.255. The Fisher’s exact is 0.057. The result is significant at p < 0.05
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had previously overdosed, including 6.12% in the last 
six months. 89.3% of recalled overdoses involved an 
emergency services response. While those that re-
ported a history of overdose also reported high risk 
injecting more (33.3% v 28.6%), this was not statisti-
cally significant, p = 0.718. Correlation between his-
tory of accidental overdose, and injecting alone was 
statistically significant (p = 0.039) (Table 3), as was 
previous history of overdose and injecting at least 
three times per day (p = 0.012) (Table 4). 
3.4. Injecting and overdose locations
86.27% indicated they would use a SIF. Partici-
pants were asked where they currently injected, had 
experienced an overdose, or knew of an overdose death 
occurring in the past. Within each of these questions 
they were asked to describe if the location was within 
a private accommodation, in a public building, or out 
in the open/street space. They were given the oppor-
tunity to give three answers to each type of question, 
as they may inject or have overdosed in more than one 
v 72.5%), the number reporting injecting at least 
three times per day was higher among those >35yrs, 
(72.7% v 55%) and high risk injecting was lower 
amongst >35yr olds (18.2% v 35.9%, Table 2). These 
findings were not statistically significant (p= 0.988, p 
= 0.290 and p = 0.287, respectively). Being homeless 
was tested for an association with the three injecting 
patterns; high risk injecting into the groin/neck, in-
jecting alone, or injecting at least three/day. Home-
less PWID reported less high risk injecting (27.3% 
v 34.5%), injected alone more (77.3% v 69.0%), and 
injecting at least three times per day close to those 
who were in stable accommodation (54.5% v 62.1%), 
but these findings were not statistically significant 
(p= 0.583, p = 0.510 and p = 0.589, respectively).
3.3. Overdose
PWID are at significant risk of accidental over-
dose, and place a large burden on the emergency ser-
vices to respond to these events. This is one of the 
main pillars on which SIFs were constructed. 58.82% 
Table 4. Association between Overdose History & Injecting Frequency
Injects at least three times daily
Accidentally overdosed?
Yes No Total
No
Count 8 13 21
% within Have you ever accidentally gone over/
overdosed? 26.7% 61.9% 41.2%
Yes
Count 22 8 30
% within Have you ever accidentally gone over/
overdosed? 73.3% 38.1% 58.8%
Total
Count 30 21 51
% within Have you ever accidentally gone over/
overdosed? 100.0% 100.0% 100.0%
The χ² statistic is 6.333. The Fisher’s exact is 0.020. The result is significant at p < 0.05
Table 5: Location type
OD Death
Is this in private accommodation
Count 35 20 36
% 26.1% 42.5% 62.06%
Is it in a public building
Count 53 15 11
% 39.5% 31.9% 18.97%
Is it in an open/street space
Count 46 12 11
% 34.3% 25.5% 18.97%
Emergency Services Count  [%] 42 [89.3%]
Total
Count 134 47 58
% 100.0% 100.0% 100.0%
Inject -Where do you usually inject?
OD-Where did you [accidentally] overdose?
Death-Where did the drug related death occur
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private, as did known deaths. Emergency services 
were asked to attend in 89.3% of overdoses.
Those in the homeless category identified inject-
ing in public buildings more (46.6% v 34.2%), but 
this was tempered by the fact that many of those in 
this category injected in their homeless emergency 
room, and this was classed as private (p = 0.345). Al-
though no difference was seen between the two age 
categories injecting on the street (37.9% v 40.0%), 
those aged 35 years or older injected more in private 
accommodation (41.4% v 21.9%), and less on the 
street (20.7% v 38.1%). This did not reach statistical 
significance (p = 0.070). Tests for an association be-
tween injecting location type and history of overdose, 
sharing injecting paraphernalia, or a history of SSTI 
in the previous three months, did not reveal large dif-
ferences (p= 0.947, p = 0.448 and p = 0.210, respec-
tively).
3.5. Geo-mapping of SIF, existing services, injecting 
and overdose Locations
A mapping exercise presented visual informa-
tion around injecting sites, locations of overdoses, 
fatal overdoses, and preferred location of the SIF. 
Participants identified where they injected, and this 
was sub typed as described above, into public build-
ings, private accommodation, or open/street space. 
Similarly participants identified where they had had 
location, and similarly may have known of an over-
dose in more than one location. Participants had no 
issue identifying multiple injecting locations, but less 
likely to identify overdose locations, and death loca-
tions (Table 5). 90.2% of respondents knew of some-
one who had died from an overdose. Users identified 
that overdose occurred relatively more commonly in 
 
 
Figure One: Fatal overdose, injecting, overdose and preferred SIF location.  Figure 1. Fat l erdose, injecti g, overd se and pre-
ferred SIF location. 
Figure Two: 1SD weighted ellipses of all locations, by behaviour type.
 
2.  1SD weighted ellipses of all l c tions, by behaviour type. 
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understand the existing PWID in terms of injecting 
risk behaviours and locations, and in defining the as-
sociated risk behaviour which establishment of a new 
SIF might address. 86.27% of participants in this 
study agreed they would use a SIF if available, and 
which compares to 71% in Sydney, while Vancouver 
reported between 37% and 92% willingness to attend 
a SIF [21, 27-29, 37, 38, 46, 48]. A high proportion of 
PWID in this study injected frequently during the day, 
and thus highlighting the need for sufficient service 
provision in terms of opening times. An overview in 
2014 of 62 SIF found that there was a wide variation 
in the available opening hours of such facilities with 
just over half providing a daily service; open on aver-
age eight hours per day [51]. 
The study provides a cross-sectional view of 
Cork city’s drug injecting practices, including risk-
taking injecting behaviours such as sharing drug tak-
ing apparel, and high risk behaviour including inject-
ing alone, and injecting into the groin and neck. Of the 
PWID in this study, 58.8% had previously overdosed, 
including 6.12% in the last 6 months, and 89.3% of 
recalled overdoses involved an emergency services 
response. This compares to a previous Irish study in 
2015, which found that 60% had an overdose history, 
with 10% in the previous 6 months, and illustrates the 
on-going need for an intervention [15]. SIF have been 
shown in many studies to prevent PWID from over-
dosing both within SIF, and to reduce overdose mor-
tality [8, 31, 32]. Studies of Insite, the SIF in Vancou-
ver, have estimated that 5% of the neighbourhood’s 
overdoses occur within the facility, but that between 
7% and 43% of the neighbourhoods overdoses may 
be further prevented outside, as a result of education 
from the SIF [34]. 
The study suggests that 25.5% of accidental 
overdoses in Cork occur on the street, with 18.9% of 
the fatal overdose recalled by PWID as having oc-
curred on the street. This compares to the estimated 
risk of overdose 10 times higher for street overdos-
es than in SIF [1]. 42.5% of overdoses in this Irish 
study occurred in private accommodation and 32.9% 
in public locations. In Norway, ambulance call out 
times were more likely to be longer to overdose call-
outs to private locations than to public locations [29]. 
This is important for the emergency services to un-
derstand, with many of these private accommodations 
representing homeless emergency rooms, reflected in 
the fact that 43.1% of participants in this study were 
categorized as currently homeless and 56.9% in sta-
ble accommodation. 21.57% reported an SSTI, and 
13.7% had attended the emergency services in the 
a history of accidental overdose, knew of an overdose 
death, and where they would subjectively like to place 
the SIF themselves. Using these GPS coordinates, the 
GIS software was able to generate maps of the data. 
The data was first mapped together, to visualize obvi-
ous outliers, and then expanded to just visualize the 
main focus of activity (Figure 1).
In Figure 2 we overlaid the weighted ellipses of 
each of the main mapping questions. While the over-
dose and death distributions are larger, which may in-
dicate the more widespread dispersion of fewer data 
points, the injecting ellipse is focused on the city cen-
tre, as is the user preferences for a SIF location. 
4. Discussion
We present here findings from an exercise un-
dertaken in a city in south Ireland to profile and map 
service user needs in the PWID population, and uti-
lize geo -mapping software to inform the location 
need of a SIF. GIS allows both static and dynamic 
illustration of public health issues, and can use sta-
tistical parameters to confine the data, and help make 
objective decisions [4, 14, 26, 36, 28, 52]. This is 
especially important in the case of SIF as it permits 
service provision, and social contexts to be visualized 
within the data, and inform policy makers of the po-
tential public health impact on PWID, related mortal-
ity and morbidity, and relevant clinical issues. Poten-
tial trends evidenced in this study include high risk 
injecting practices into the groin and neck, and in-
jecting alone, and future impact studies can compare 
whether an improvement can be seen in such prac-
tices with provision of a SIF in a targeted location. 
As this study found an association between injecting 
alone (p = 0.039), or injecting at least three times per 
day (p = 0.012) and overdose, GIS could be used to 
map where such activities are concentrated, and again 
whether this is focused in public toilets or homeless 
accommodation. 
The provision of SIF are often in response to 
community outcry around public injecting, and its as-
sociated problems, and only secondarily to the public 
health issue of injecting drug users themselves [44]. 
The study emphasises the importance of consultation 
with the PWID community in order to best under-
stand where injecting and overdose sites are located, 
in order to accurately establish where best to situate a 
SIF, and in order to full engage with the local commu-
nities. This may help reduce the objections of “Not 
In My Backyard”, and instead bring pragmatism to 
this public health debate [5, 39]. It will also better 
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form the new national drug strategy, and to identify 
possible deficiencies and solutions to improving the 
current and future locations and availability of treat-
ment in the City of Cork, Ireland. This could improve 
treatment for persons who inject drugs and reduce 
waiting times for those wishing to access treatment. 
It may also inform treatment and harm reduction ser-
vices in the design and implementation of an infor-
mation leaflet for PWID and their service providers 
to signpost where services are currently located in 
relation to need.
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[27, 40]. 92.16% had been tested for HIV/HCV, only 
50.98% recalled being tested in the last 6 months, but 
54.9% reported sharing equipment/needles. Current 
Irish data of PWID places the estimated number in-
fected with HCV at 12, 423 (95%CI: 10 799-13 161) 
[2]. SIF reduce HIV/HCV transmission by reducing 
needle sharing and through education [1, 22, 23]. 
Vancouver’s SIF has been shown to reduce needle-
sharing by as much as 70% [20]. Many HCV infec-
tions remain undiagnosed with as many as two in five 
PWID living with HCV, but half undiagnosed. One 
in four PWID have not been vaccinated for Hepatitis 
B, and one in three PWID reported having had bacte-
rial infections at injection sites [37]. There is recent 
evidence that opening a SIF can further change drug 
use behaviour and syringe disposal. In a large Dan-
ish study, drug users reported being less stressed or 
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[25]. Between 2004 and 2012, Barcelona reported a 
fourfold decrease in syringe litter [47].
Limitations
The sample size is small, and so limits the appli-
cability to other cities. There is acknowledged dupli-
cation in the recounting of known overdose deaths, as 
the PWID population is small and closely connected, 
which means that any death within this community is 
communicated throughout the population. The pool 
of respondents, while representing current injecting 
practices, may not capture the most chaotic users, 
who do not attend any of the survey sites, and equally 
may not capture the early intravenous drug users, as 
they may as yet not attend services for assistance. A 
SIF would hope to capture both of these populations. 
5. Conclusions
The study provides an understanding of PWID 
profile and risk behaviours, alongside a geospatial 
analysis of injecting, overdose and potential location 
of a SIF in Cork, Ireland. The findings are intended to 
inform SIF location, and would allow dynamic com-
parison of both geographic and behavioural changes 
injecting drug use over time, post SIF provision. Ul-
timately, the benefits of this mapping study are to in-
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